Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation

被引:22
|
作者
Bastidas-Mora, Gabriela [1 ,2 ]
Bea, Silvia [1 ,2 ,3 ,4 ,5 ]
Navarro, Alba [3 ,5 ]
Gine, Eva [1 ,2 ,3 ,5 ]
Costa, Dolors [1 ,2 ,3 ,5 ]
Delgado, Julio [1 ,2 ,3 ,5 ]
Baumann, Tycho [1 ,2 ,5 ,6 ]
Magnano, Laura [1 ,2 ,3 ]
Rivas-Delgado, Alfredo [1 ,2 ,3 ]
Villamor, Neus [1 ,2 ,3 ,5 ]
Colomer, Dolors [1 ,2 ,3 ,4 ,5 ]
Lopez-Guerra, Monica [1 ,2 ,3 ,5 ]
Rozman, Maria [1 ,2 ,3 ]
Balague, Olga [1 ,2 ,3 ,5 ]
Martinez, Daniel [1 ,2 ,5 ]
Baptista, Maria Joao [7 ]
Escoda, Lourdes [8 ]
Alcoceba, Miguel [5 ,9 ]
Blanes, Margarita [10 ]
Climent, Fina [11 ]
Campo, Elias [1 ,2 ,3 ,4 ,5 ]
Wotherspoon, Andrew [12 ]
Lopez-Guillermo, Armando [1 ,2 ,3 ,4 ,5 ]
Matutes, Estella [1 ,2 ]
机构
[1] Hosp Clin Barcelona, Hematol Dept, Barcelona, Spain
[2] Hosp Clin Barcelona, Hematopathol Sect, Pathol Dept, Barcelona, Spain
[3] Inst Invest Biomed August Pi i Sunyer IDIBAP, Barcelona, Spain
[4] Univ Barcelona, Barcelona, Spain
[5] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
[6] Hosp 12 Octubre, Serv Hematol, Madrid, Spain
[7] Josep Carreras Leukaemia Res Inst IJC, ICO Hosp Germans Trias & Pujol, Barcelona, Spain
[8] ICO Hosp Joan XXIII, Tarragona, Spain
[9] Univ Hosp Salamanca HUS IBSAL, Dept Hematol, Canc Res Inst Salamanca IBMCC USAL CSIC, Salamanca, Spain
[10] Hosp Gen Univ Elda, Alicante, Spain
[11] Hosp Univ Bellvitge IDIBELL, Dept Pathol, Barcelona, Barcelona, Spain
[12] Royal Marsden NHS Fdn Trust, London, England
关键词
splenic marginal zone lymphoma; histological transformation; complex karyotype; prognostic factors; survival; B-CELL LYMPHOMA; FOLLICULAR LYMPHOMA; VILLOUS LYMPHOCYTES; RESPONSE CRITERIA; RISK; RITUXIMAB; SURVIVAL; SPLENECTOMY; MULTICENTER; SERIES;
D O I
10.1111/bjh.17815
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We describe 36 patients with splenic marginal zone lymphoma (SMZL) with transformation (SMZL-T), including 15 from a series of 84 patients with SMZL diagnosed at the Hospital Clinic of Barcelona (HCB) and 21 diagnosed with SMZL-T in other centres. In the HCB cohort, the cumulative incidence of transformation at 5 years was 15%. Predictors for transformation were cytopenias, hypoalbuminaemia, complex karyotype (CK) and both the Intergruppo Italiano Linfomi (ILL) and simplified Haemoglobin, Platelet count, lactate dehydrogenase (LDH) and extrahilar Lymphadenopathy (HPLL)/ABC scores (P < 0 center dot 05). The only independent predictor for transformation in multivariate analysis was CK [hazard ratio (HR) 4 center dot 025, P = 0 center dot 05]. Patients with SMZL-T had a significantly higher risk of death than the remainder (HR 3 center dot 89, P < 0 center dot 001). Of the 36 patients with SMZL-T, one developed Hodgkin lymphoma and 35 a diffuse large B-cell lymphoma, 71% with a non-germinal centre phenotype. The main features were B symptoms, lymphadenopathy, and high serum LDH. CK was observed in 12/22 (55%) SMZL-T and fluorescence in situ hybridisation detected abnormalities of MYC proto-oncogene, basic helix-loop-helix transcription factor (MYC), B-cell leukaemia/lymphoma 2 (BCL2) and/or BCL6 in six of 14 (43%). In all, 21 patients received immunochemotherapy, six chemotherapy, one radiotherapy and three splenectomy. The complete response (CR) rate was 61% and the median survival from transformation was 4 center dot 92 years. Predictors for a worse survival in multivariate analysis were high-risk International Prognostic Index (HR 5 center dot 294, P = 0 center dot 016) and lack of CR (HR 2 center dot 67, P < 0 center dot 001).
引用
收藏
页码:146 / 155
页数:10
相关论文
共 50 条
  • [1] Splenic marginal zone lymphoma: disease features and management
    Matutes, Estella
    EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (06) : 735 - 745
  • [2] Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma
    Olszewski, Adam J.
    Ali, Shihab
    ANNALS OF HEMATOLOGY, 2014, 93 (03) : 449 - 458
  • [3] Surgical management of splenic marginal zone lymphoma
    Kennedy, N. D.
    Le, G. N.
    Kelly, M. E.
    Harding, T.
    Fadalla, K.
    Winter, D. C.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2018, 187 (02) : 343 - 347
  • [4] Clinical and biological diversity of splenic marginal zone lymphoma
    Matutes, Estella
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (09) : 1185 - 1189
  • [5] Superior outcome for splenectomised patients in a population-based study of splenic marginal zone lymphoma in Sweden
    Sima, Andreea
    Hollander, Peter
    Baecklund, Eva
    Smedby, Karin E.
    Enblad, Gunilla
    Amini, Rose-Marie
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (03) : 568 - 579
  • [6] Treatment of Splenic Marginal Zone Lymphoma With Rituximab Monotherapy: Progress Report and Comparison With Splenectomy
    Kalpadakis, Christina
    Pangalis, Gerassimos A.
    Angelopoulou, Maria K.
    Sachanas, Sotirios
    Kontopidou, Flora N.
    Yiakoumis, Xanthi
    Kokoris, Stella I.
    Dimitriadou, Evagelia M.
    Dimopoulou, Maria N.
    Moschogiannis, Maria
    Korkolopoulou, Penelope
    Kyrtsonis, Marie-Christine
    Siakantaris, Marina P.
    Papadaki, Theodora
    Tsaftaridis, Panayiotis
    Plata, Eleni
    Papadaki, Helen E.
    Vassilakopoulos, Theodoros P.
    ONCOLOGIST, 2013, 18 (02): : 190 - 197
  • [7] Autoimmune Hemolytic Anemia as a Risk Factor of Poor Outcome in Patients with Splenic Marginal Zone Lymphoma
    Fodor, Aniko
    Molnar, Miklos Zsolt
    Krenacs, Laszlo
    Bagdi, Eniko
    Csomor, Judit
    Matolcsy, Andras
    Demeter, Judit
    PATHOLOGY & ONCOLOGY RESEARCH, 2009, 15 (04) : 597 - 603
  • [8] Validation of the simplified prognostic score for splenic marginal zone lymphoma of the Splenic Marginal Zone Lymphoma Working Group
    Kalpadakis, Christina
    Pangalis, Gerassimos A.
    Angelopoulou, Maria K.
    Sachanas, Sotirios
    Kontopidou, Flora
    Moschogiannis, Maria
    Ximeri, Maria
    Tsirkinidis, Pantelis
    Yiakoumis, Xanthi
    Papadaki, Helen A.
    Vassilakopoulos, Theodoros P.
    LEUKEMIA & LYMPHOMA, 2014, 55 (11) : 2640 - 2642
  • [9] Splenic marginal zone lymphoma
    Piris, Miguel A.
    Onaindia, Arantza
    Mollejo, Manuela
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2017, 30 (1-2) : 56 - 64
  • [10] Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia
    Xing, Katharine H.
    Kahlon, Amrit
    Skinnider, Brian F.
    Connors, Joseph M.
    Gascoyne, Randy D.
    Sehn, Laurie H.
    Savage, Kerry J.
    Slack, Graham W.
    Shenkier, Tamara N.
    Klasa, Richard
    Gerrie, Alina S.
    Villa, Diego
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (04) : 520 - 527